Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Hemab Therapeutics Holdings, Inc.: Filed a restated certificate of incorporation that increases authorized common stock, eliminates preferred stock references, authorizes undesignated preferred stock, establishes a classified board, modifies director removal and vacancy procedures, eliminates stockholder action by written consent and (effective 2026-05-04).
- Change
- charter amendment
- Effective
- 2026-05-04
Exact text from the filing
On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Hemab Therapeutics Holdings, Inc.: Amended and restated bylaws to eliminate stockholder action by written consent, establish procedures for stockholder proposals and director nominations, and conform to the restated certificate (effective 2026-05-04).
- Change
- bylaw amendment
- Effective
- 2026-05-04
Exact text from the filing
On May 4, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), which were previously approved by the Company’s board of directors and stockholders, became effective upon the closing of the IPO.
View on SEC.gov